Highlights Replimune Group, Inc.

Equities

REPL

US76029N1063

Real-time Estimate Cboe BZX Other stock markets 18:09:24 13/05/2024 BST			5-day change	1st Jan Change
6.66 ^USD	+3.90%		-4.42%	-20.52%

04-08	Replimune Group Provides Interim Results for Skin Cancer Therapy	MT
03-26	Replimune Group, Inc. Announces Management Changes	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Replimune Group Provides Interim Results for Skin Cancer Therapy	04-08	MT
Replimune Group, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-08	CI
Replimune Group, Inc. Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failure Melanoma and Non-Melanoma Skin Cancers	12-05	CI
Replimune Group, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-07	CI
Replimune Group, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	03/08/23	CI
Replimune Group, Inc. Presents RP1 Data from the IGNYTE Anti-PD1 Failure Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology Annual Meeting	03/06/23	CI
Replimune Group's Fiscal Q4 Net Loss Widens; Chief Financial Officer Jean Franchi to Depart	18/05/23	MT
Replimune Group, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	18/05/23	CI
Replimune's Fiscal Q3 Loss Widens; Company Sees Cash Runway to Fund Operations Into Second Half of 2025	09/02/23	MT
2015 Enterprise Management Incentive Share Option Plan	09/02/23	AQ
Replimune Group, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	09/02/23	CI
Replimune, Roche to Collaborate on Cancer Drug Development Program	07/12/22	MT
Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update	07/12/22	CI
Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 in Colorectal Cancer and Hepatocellular Carcinoma	07/12/22	CI
2015 Enterprise Management Incentive Share Option Plan	03/11/22	AQ
Replimune Group, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	03/11/22	CI
2015 Enterprise Management Incentive Share Option Plan	04/08/22	AQ
Replimune Group, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022	04/08/22	CI
Replimune Group's Fiscal Q4 Net Loss Widens	19/05/22	MT
REPLIMUNE GROUP, INC. Management's discussion and analysis of financial condition and results of operations (form 10-K)	19/05/22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Replimune Group, Inc.

Equities

REPL

US76029N1063

Highlights

Filters